Fresenius Kabi Announces Launch of Oxaliplatin Injection, USP
10:21 EDT 9 Aug 2012 | Businesswire
This article has expired, however you can still
download the PDF.
Preview:
Fresenius Kabi today announced that is has launched Oxaliplatin
Injection, USP.
Oxaliplatin Injection, USP, is a platinum-based drug used in combination
with infusional 5-fluorouracil/leucovorin, and indicated for adjuv...
Other Sources for this Article
Fresenius Kabi
Matt Kuhn, 847-969-8026
matt.kuhn@fresenius-kabi.com
More From BioPortfolio on "Fresenius Kabi Announces Launch of Oxaliplatin Injection, USP"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
